PhaseBio Pharmaceuticals Q3 EPS $(0.4) Misses $(0.37) Estimate, Sales $200K Miss $230K Estimate

PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported quarterly losses of $(0.4) per share which missed the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 96.17 percent increase over losses of $(10.45) per

Benzinga · 11/14/2019 13:04

PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported quarterly losses of $(0.4) per share which missed the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 96.17 percent increase over losses of $(10.45) per share from the same period last year. The company reported quarterly sales of $200 thousand which missed the analyst consensus estimate of $230 thousand by 13.04 percent. This is a 50.00 percent decrease over sales of $400 thousand the same period last year.